Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor‐Mediated Recycling of HL2351, a Novel Hybrid Fc‐Fused Interleukin‐1 Receptor Antagonist, to Optimize Dosage Regimen

• Autori principali: Lien Ngo (Autore), Jaeseong Oh (Autore), Anhye Kim (Autore), Hyun‐moon Back (Autore), Won‐ho Kang (Autore), Jung‐woo Chae (Autore), Hwi‐yeol Yun (Autore), Howard Lee (Autore)
• Natura: Libro
• Pubblicazione: Wiley, 2020-10-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

HL2351 (hIL‐1Ra‐hyFc) is a novel recombinant protein formed by the fusion of two human interleukin‐1 receptor antagonist components into one antibody‐derived fragment crystallizable portion. Although HL2351 has a pharmacological mechanism of action similar to that of anakinra as a commercialized bio...